NCCN-Recommended Dosing Schedule for Paclitaxel 80 mg/m² and Carboplatin AUC 2
According to NCCN guidelines, paclitaxel 60 mg/m² (not 80 mg/m²) combined with carboplatin AUC 2 is administered weekly for 18 consecutive weeks, not on days 1,8, and 15 of a 28-day cycle. 1
The Correct NCCN Regimens
The NCCN guidelines for ovarian cancer specify two distinct paclitaxel/carboplatin dosing schedules:
Weekly Regimen (18 weeks continuous)
- Paclitaxel 60 mg/m² IV over 1 hour followed by carboplatin AUC 2 IV over 30 minutes
- Given weekly for 18 weeks (not in 28-day cycles)
- Category 1 recommendation 1
Dose-Dense Regimen (21-day cycles)
- Paclitaxel 80 mg/m² IV over 1 hour on days 1,8, and 15
- Carboplatin AUC 5-6 IV over 1 hour on day 1 only
- Repeated every 3 weeks (21 days) for 6 cycles
- Category 1 recommendation 1
Critical Distinction
The dose you're asking about (paclitaxel 80 mg/m² with carboplatin AUC 2 on days 1,8,15 of a 28-day cycle) does not appear in NCCN guidelines for ovarian cancer. This appears to be a hybrid schedule that mixes elements from different regimens.
The 80 mg/m² paclitaxel dose is used in the dose-dense regimen, but that regimen pairs it with carboplatin AUC 5-6 given only on day 1 of a 21-day cycle—not with weekly carboplatin AUC 2. 1
The weekly carboplatin AUC 2 schedule exists in NCCN guidelines, but uses paclitaxel 60 mg/m² (not 80 mg/m²) and is given continuously for 18 weeks without the week-off structure of a 28-day cycle. 1
Clinical Context
While research studies have explored weekly paclitaxel 80 mg/m² with carboplatin AUC 2 on days 1,8,15 of 28-day cycles 2, 3, 4, this specific schedule is not endorsed as a Category 1 recommendation in NCCN guidelines for first-line ovarian cancer treatment. The NCCN panel has established the two regimens above based on randomized trial data supporting their efficacy and safety profiles.